177Lu-NeoBOMB1
- Generic Name
- 177Lu-NeoBOMB1
NEPC Study: An Exploratory Safety and Efficacy Study With PSMA, SSTR2 and GRPR Targeted Radioligand Therapy in Metastatic Neuroendocrine Prostate Cancer.
- Conditions
- Metastatic Neuroendocrine Prostate Cancer
- Interventions
- Drug: [68Ga]Ga-PSMA-11Drug: Gonadotropin-releasing hormone (GnRH) analoguesDrug: Antiemetics & antinauseants
- First Posted Date
- 2024-04-23
- Last Posted Date
- 2025-04-04
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 36
- Registration Number
- NCT06379217
- Locations
- 🇺🇸
Seattle Cancer Care Alliance, Seattle, Washington, United States
🇺🇸Nebraska Cancer Specialists, Omaha, Nebraska, United States
🇺🇸Memorial Sloan Kettering Cancer Ctr, New York, New York, United States
A Phase I/II, Dose Finding and Optimization Study of [177Lu]Lu-NeoB in Combination With Capecitabine in Patients With GRPR+, ER+, HER2- Metastatic Breast Cancer After Progression on Previous Endocrine Therapy in Combination With a CDK4/6 Inhibitor.
- Conditions
- Breast Cancer
- Interventions
- First Posted Date
- 2024-02-08
- Last Posted Date
- 2025-05-21
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 58
- Registration Number
- NCT06247995
- Locations
- 🇺🇸
UCLA Medical Center, Los Angeles, California, United States
🇺🇸Hoag Memorial Hospital Presbyterian, Newport Beach, California, United States
🇺🇸Uni Of TX MD Anderson Cancer Cntr, Houston, Texas, United States
[177Lu]Lu-NeoB in Combination With Ribociclib and Fulvestrant in Participants With ER+, HER2- and GRPR+ Advanced Breast Cancer
- Conditions
- Breast Cancer
- Interventions
- First Posted Date
- 2023-05-23
- Last Posted Date
- 2025-05-21
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 48
- Registration Number
- NCT05870579
- Locations
- 🇺🇸
Hoag Memorial Hospital Presbyterian, Newport Beach, California, United States
🇺🇸University of Pennsylvania, Philadelphia, Pennsylvania, United States
🇺🇸MD Anderson Cancer Center, Houston, Texas, United States
Dose Finding Study of [177Lu]Lu-NeoB in Newly Diagnosed Glioblastoma and in Recurrent Glioblastoma
- Conditions
- Newly Diagnosed and Recurrent Glioblastoma
- Interventions
- First Posted Date
- 2023-02-22
- Last Posted Date
- 2025-05-21
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 48
- Registration Number
- NCT05739942
- Locations
- 🇺🇸
University of California LA, Los Angeles, California, United States
🇺🇸University of Colorado Denver, Aurora, Colorado, United States
🇺🇸Dana Farber Cancer Institute, Boston, Massachusetts, United States
[177Lu]-NeoB in Patients With Advanced Solid Tumors and With [68Ga]-NeoB Lesion Uptake
- Conditions
- Neoplasms
- Interventions
- First Posted Date
- 2019-03-13
- Last Posted Date
- 2025-01-23
- Lead Sponsor
- Advanced Accelerator Applications
- Target Recruit Count
- 51
- Registration Number
- NCT03872778
- Locations
- 🇺🇸
City of Hope, Duarte, California, United States
🇺🇸Stanford University, Stanford, California, United States
🇺🇸John Hopkins University, Baltimore, Maryland, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.